Serous endometrial cancers that mimic endometrioid adenocarcinomas - A clinicopathologic and immunohistochemical study of a group of problematic cases

被引:103
作者
Darvishian, T
Hummer, AJ
Thaler, HT
Bhargava, R
Linkov, I
Asher, M
Soslow, RA
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA
关键词
uterine serous carcinoma; endometrioid carcinoma; p53; PTEN; beta-catenin;
D O I
10.1097/00000478-200412000-00004
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Background: Uterine serous carcinomas (USCs) can exhibit an architecturally well-differentiated tubuloglandular morphology with or without an accompanying papillary growth pattern. These features make it difficult to distinguish USCs from endometrial endometrioid carcinomas (EECs). Given the aggressive behavior of USC, compared with EEC, and differences in management, it is important to correctly classify endometrial carcinomas that exhibit a tubuloglandular architecture with high nuclear grade. We sought an immunohistochemical panel to minimize subjectivity in the distinction of USC from EEC. Materials and Methods: We identified 8 problematic endometrial cancers, exhibiting a tubuloglandular growth pattern and high nuclear grade, whose classification as EEC or USC was debated or resulted in disagreement. We selected 13 cases of International Federation of Gynecology and Obstetrics (FIGO) grade 2 EEC and 16 cases of USC as controls. An immunohistochemical panel, including p53, P-catenin, cyclin D1, estrogen receptor (ER), progesterone receptor (PR), and PTEN, was evaluated. Results: As a group, the clinical features and immunoprofile of the study cases resembled those of the serous controls. The study cases expressed p53, beta-catenin, cyclin D1, and ER and PR, and showed loss of PTEN in 75%, 12.5%, 0%, 37.5%, 37.5%, and 12.5% of cases, respectively. p53, P-catenin, cyclin D1, ER and PR expression, and PTEN loss were seen in 87.5%, 0%,19%, 31%,12%, and 0% of the serous controls and in 7%, 70%, 54%, 92%, 92%, and 61.5% of the endometrioid controls, respectively. The combination of lack of p53 expression, positive PR expression, and loss of PTEN best distinguished between EEC and USC using discriminant analysis (multivariate P = 0.008, <0.001, and 0.05, respectively). Conclusion: In endometrial carcinomas exhibiting high nuclear grade and low architectural grade, using a panel of immunohistochemical stains may facilitate the distinction of USC from EEC. Our clinical and immunohistochemical data also support the concept that there is a group of endometrial adenocarcinomas composed of tubular glands that are indeed serous carcinomas.
引用
收藏
页码:1568 / 1578
页数:11
相关论文
共 48 条
  • [1] Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium
    Al Kushi, A
    Lim, P
    Aquino-Parsons, C
    Gilks, CB
    [J]. MODERN PATHOLOGY, 2002, 15 (04) : 365 - 371
  • [2] Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometrioid FIGO Grade 3 cancer?
    Alektiar, KM
    McKee, A
    Lin, O
    Venkatraman, E
    Zelefsky, MJ
    McKee, B
    Hoskins, WJ
    Barakat, RR
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 54 (01): : 79 - 85
  • [3] Extended surgical staging for uterine papillary serous carcinoma: Survival outcome of locoregional (Stage I-III) disease
    Bristow, RE
    Asrari, F
    Trimble, EL
    Montz, FJ
    [J]. GYNECOLOGIC ONCOLOGY, 2001, 81 (02) : 279 - 286
  • [4] P53-EXPRESSION IN NEOPLASMS OF THE UTERINE CORPUS
    BUR, ME
    PERLMAN, C
    EDELMANN, L
    FEY, E
    ROSE, PG
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1992, 98 (01) : 81 - 87
  • [5] Cairns P, 1997, CANCER RES, V57, P4997
  • [6] Stage IA uterine serous carcinoma - A study of 13 cases
    Carcangiu, ML
    Tan, LK
    Chambers, JT
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1997, 21 (12) : 1507 - 1514
  • [7] IMMUNOHISTOCHEMICAL EVALUATION OF ESTROGEN AND PROGESTERONE-RECEPTOR CONTENT IN 183 PATIENTS WITH ENDOMETRIAL CARCINOMA .1. CLINICAL AND HISTOLOGIC CORRELATIONS
    CARCANGIU, ML
    CHAMBERS, JT
    VOYNICK, IM
    PIRRO, M
    SCHWARTZ, PE
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1990, 94 (03) : 247 - 254
  • [8] Papillary carcinoma of the endometrium: Morphometric predictors of survival
    Demopoulos, RI
    Genega, E
    Vamvakas, E
    Carlson, E
    Mittal, K
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 1996, 15 (02) : 110 - 118
  • [9] Dunton C J, 1991, Obstet Gynecol Surv, V46, P97, DOI 10.1097/00006254-199102000-00014
  • [10] Fukuchi T, 1998, CANCER RES, V58, P3526